Bristol Health
Partners
  • Sign up to our newsletter
  • Accessibility
  • Contact
  • Members
  • About us
  • Health Integration Teams
  • Our research
  • Blog
  • News
  • Events
  • Our Using Data Better programme
  • COVID-19
  • REACH

Latest news

« Back to news

£4.1 million cost saving forecast as result of safer syringes

18 November 2019

Work conducted by members of our Drug and Alcohol HIT has led to ‘low dead space’ syringes being phased into Bristol’s needle and syringe programme.

A low dead space syringe has less space between the needle and the plunger when it’s fully pushed in, compared to traditional injecting equipment. It also has a detachable needle. The ‘dead’ space in a syringe holds blood after it’s been used. Previous research has found that low dead space syringes could reduce the chance of spreading infections, if they’re re-used or shared.


Phasing in low dead space syringes is forecast to result in a £4.1 million cost saving over the next 50 years through reduction in hepatitis C transmission and treatment. The initiative is also expected to result in quality-adjusted life year gains of 1,000 years over the same time period.

Find out more about the low dead space project.

£4.1 million cost saving forecast as result of safer syringes
Tags
Drug and Alcohol HIT Health campaigns HIT updates 2018-19

Our partners

Bristol City Council
North Somerset Council
South Gloucestershire Council
University of Bristol
University of the West of England
Sirona
NHS
Avon and Wiltshire Mental Health Partnership NHS Trust
Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group
NHS Blood and Transplant
North Bristol NHS Trust
University Hospitals Bristol and Weston NHS Foundation Trust
powered by Hummingbird CMS